A pilot study on reparixin, a CXCR1/2 antagonist, to assess safety and efficacy in attenuating ischaemia-reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery

Clinical and Experimental Immunology

Volumn 180, Issue 1, 2015, Pages 131-142

  Opfermann, P ^a   Derhaschnig, U ^a   Felli, A ^a   Wenisch, J ^a   Santer, D ^b   Zuckermann, A ^a   Dworschak, M ^a   Jilma, B ^a   Steinlechner, B ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Hietzing Hospital   (Austria)

Author keywords

Cardiopulmonary bypass; CXCL8; CXCR1 2; Phase II study; Postoperative inflammation

Indexed keywords

CREATINE KINASE; CREATINE KINASE MB; DOBUTAMINE; INTERLEUKIN 8; NORADRENALIN; PLACEBO; REPARIXIN; TROPONIN T; 2-(4-ISOBUTYLPHENYL)PROPIONYLMETHANESULFONAMIDE; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; SULFONAMIDE;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CHEST TUBE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEMALE; FLUID BALANCE; GRANULOCYTOSIS; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; INFLAMMATION; LENGTH OF STAY; LOADING DRUG DOSE; MALE; NEUTROPHIL; OUTCOME ASSESSMENT; PARALLEL DESIGN; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL (TOPIC); PILOT STUDY; PLEURA EFFUSION; PNEUMONIA; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REOPERATION; REPERFUSION INJURY; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; LEUKOCYTE COUNT; METABOLISM; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATIONS; PROCEDURES; TIME FACTOR;

AGED; CORONARY ARTERY BYPASS; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; NEUTROPHILS; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B; SULFONAMIDES; TIME FACTORS;

EID: 84924288865     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12488     Document Type: Article

References (53)

1. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4:540-550.
2. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 2000; 12:336-341.
3. Konrad FM, Reutershan J. CXCR2 in acute lung injury. Mediators Inflamm 2012; 2012:740987.
4. Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity 2012; 36:705-716.
5. Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and functional expression of a human interleukin-8 receptor. Science 1991; 253:1278-1280.
6. Ahuja SK, Lee JC, Murphy PM. CXC chemokines bind to unique sets of selectivity determinants that can function independently and are broadly distributed on multiple domains of human interleukin-8 receptor B. Determinants of high affinity binding and receptor activation are distinct. J Biol Chem 1996; 271:225-232.
7. Murphy PM, Tiffany HL. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science 1991; 253:1280-1283.
8. Robertson MJ. Role of chemokines in the biology of natural killer cells. J Leukoc Biol 2002; 71:173-183.
9. Tani K, Su SB, Utsunomiya I, Oppenheim JJ, Wang JM. Interferon-gamma maintains the binding and functional capacity of receptors for IL-8 on cultured human T cells. Eur J Immunol 1998; 28:502-507.
10. Burdon PC, Martin C, Rankin SM. Migration across the sinusoidal endothelium regulates neutrophil mobilization in response to ELR + CXC chemokines. Br J Haematol 2008; 142:100-108.
11. Baggiolini M, Loetscher P. Chemokines in inflammation and immunity. Immunol Today 2000; 21:418-420.
12. Bizzarri C, Beccari AR, Bertini R, Cavicchia MR, Giorgini S, Allegretti M. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther 2006; 112:139-149.
13. Matsushima K, Morishita K, Yoshimura T etal. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med 1988; 167:1883-1893.
14. Campbell LM, Maxwell PJ, Waugh DJ. Rationale and means to target pro-inflammatory interleukin-8 (CXCL8) signaling in cancer. Pharmaceuticals 2013; 6:929-959.
15. Bertini R, Allegretti M, Bizzarri C etal. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci USA 2004; 101:11791-11796.
16. Citro A, Cantarelli E, Maffi P etal. CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. J Clin Invest 2012; 122:3647-3651.
17. Cavalieri B, Mosca M, Ramadori P etal. Neutrophil recruitment in the reperfused-injured rat liver was effectively attenuated by repertaxin, a novel allosteric noncompetitive inhibitor of CXCL8 receptors: a therapeutic approach for the treatment of post-ischemic hepatic syndromes. Int J Immunopathol Pharmacol 2005; 18:475-486.
18. Cugini D, Azzollini N, Gagliardini E etal. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int 2005; 67:1753-1761.
19. Souza DG, Bertini R, Vieira AT etal. Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br J Pharmacol 2004; 143:132-142.
20. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 2002; 97:215-252.
21. Hausenloy DJ, Erik Botker H, Condorelli G etal. Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2013; 98:7-27.
22. Liakopoulos OJ, Schmitto JD, Kazmaier S etal. Cardiopulmonary and systemic effects of methylprednisolone in patients undergoing cardiac surgery. Ann Thorac Surg 2007; 84:110-118.
23. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004; 61:481-497.
24. Francischetti I, Moreno JB, Scholz M, Yoshida WB. Leukocytes and the inflammatory response in ischemia-reperfusion injury. Rev Bras Cir Cardiovasc 2010; 25:575-584.
25. Thielmann M, Kottenberg E, Kleinbongard P etal. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet 2013; 382:597-604.
26. Leitner JM, Mayr FB, Firbas C etal. Reparixin, a specific interleukin-8 inhibitor, has no effects on inflammation during endotoxemia. Int J Immunopathol Pharmacol 2007; 20:25-36.
27. Puri GD, Murthy SS. Bispectral index monitoring in patients undergoing cardiac surgery under cardiopulmonary bypass. Eur J Anaesthesiol 2003; 20:451-456.
28. Derhaschnig U, Bergmair D, Marsik C, Schlifke I, Wijdenes J, Jilma B. Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia. Crit Care Med 2004; 32:1136-1140.
29. Nashef SA, Roques F, Sharples LD etal. EuroSCORE II. Eur J Cardiothorac Surg 2012; 41:734-744; discussion 44-5.
30. Sadik CD, Kim ND, Luster AD. Neutrophils cascading their way to inflammation. Trends Immunol 2011; 32:452-460.
31. Eash KJ, Greenbaum AM, Gopalan PK, Link DC. CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. J Clin Invest 2010; 120:2423-2431.
32. Moriconi A, Cesta MC, Cervellera MN etal. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem 2007; 50:3984-4002.
33. Chishti AD, Dark JH, Kesteven P etal. Expression of chemokine receptors CXCR1 and CXCR2 during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2001; 122:1162-1166.
34. Singh V, Raghuwanshi SK, Smith N, Rivers EJ, Richardson RM. G Protein-coupled receptor kinase-6 interacts with activator of G protein signaling-3 to regulate CXCR2-mediated cellular functions. J Immunol 2014; 192:2186-2194.
35. Williams MR, Azcutia V, Newton G, Alcaide P, Luscinskas FW. Emerging mechanisms of neutrophil recruitment across endothelium. Trends Immunol 2011; 32:461-469.
36. Pruenster M, Mudde L, Bombosi P etal. The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat Immunol 2009; 10:101-108.
37. Mei J, Liu Y, Dai N etal. CXCL5 regulates chemokine scavenging and pulmonary host defense to bacterial infection. Immunity 2010; 33:106-117.
38. Tarzami ST. Chemokines and inflammation in heart disease: adaptive or maladaptive? Int J Clin Exp Med 2011; 4:74-80.
39. Tarzami ST, Miao W, Mani K etal. Opposing effects mediated by the chemokine receptor CXCR2 on myocardial ischemia-reperfusion injury: recruitment of potentially damaging neutrophils and direct myocardial protection. Circulation 2003; 108:2387-2392.
40. Chen J, Chemaly E, Liang L etal. Effects of CXCR4 gene transfer on cardiac function after ischemia-reperfusion injury. Am J Pathol 2010; 176:1705-1715.
41. LaRocca TJ, Schwarzkopf M, Altman P etal. beta2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J Cardiovasc Pharmacol 2010; 56:548-559.
42. Prowle JR, Echeverri JE, Ligabo EV, Ronco C, Bellomo R. Fluid balance and acute kidney injury. Nat Rev Nephrol 2010; 6:107-115.
43. Silva JM, Jr, de Oliveira AM, Nogueira FA etal. The effect of excess fluid balance on the mortality rate of surgical patients: a multicenter prospective study. Crit Care 2013; 17:R288.
44. Heit B, Robbins SM, Downey CM etal. PTEN functions to 'prioritize' chemotactic cues and prevent 'distraction' in migrating neutrophils. Nat Immunol 2008; 9:743-752.
45. Kim D, Haynes CL. Neutrophil chemotaxis within a competing gradient of chemoattractants. Anal Chem 2012; 84:6070-6078.
46. Di Cioccio V, Strippoli R, Bizzarri C etal. Key role of proline-rich tyrosine kinase 2 in interleukin-8 (CXCL8/IL-8)-mediated human neutrophil chemotaxis. Immunology 2004; 111:407-415.
47. Hennein HA, Ebba H, Rodriguez JL etal. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994; 108:626-635.
48. Hausenloy D, Kunst G, Boston-Griffiths E etal. The effect of cyclosporin-A on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: a randomised controlled clinical trial. Heart 2014; 100:544-549.
49. Muller-Edenborn B, Frick R, Piegeler T etal. Volatile anaesthetics reduce neutrophil inflammatory response by interfering with CXC receptor-2 signalling. Br J Anaesth 2015; 114:143-149.
50. Reutershan J, Morris MA, Burcin TL etal. Critical role of endothelial CXCR2 in LPS-induced neutrophil migration into the lung. J Clin Invest 2006; 116:695-702.
51. Sue RD, Belperio JA, Burdick MD etal. CXCR2 is critical to hyperoxia-induced lung injury. J Immunol 2004; 172:3860-3868.
52. Zarbock A, Allegretti M, Ley K. Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice. Br J Pharmacol 2008; 155:357-364.
53. Holz O, Khalilieh S, Ludwig-Sengpiel A etal. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 2010; 35:564-570.